aetna coverage for glp 1 Medicare GLP-1 Bridge and Eligibility aetna glp-1 coverage policy MCT2D

Results confirmed liraglutide's superiority: HbA1c reduction: -1.48% (liraglutide) vs -1.28% (exenatide ER) Weight loss: -3.57 kg (liraglutide) vs -2.68 kg (exenatide ER) Weight Loss Comparison# Exenatide (DURATION Program)# Exenatide was developed for type 2 diabetes, not weight management: DURATION-1: 3.7 kg weight loss with Bydureon over 30 weeks DURATION-5: 2.3 kg weight loss over 24 weeks Three-year extension: 2.3 kg sustained weight reduction No FDA approval for chronic weight management Liraglutide (SCALE Program)# Liraglutide was specifically developed for obesity at the higher 3.0 mg dose: SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015): 8.0% mean weight loss at 56 weeks 63.2% achieved 5% or more weight loss

Oxyntomodulin and glicentin may predict the effect of bariatric surgery on food preferences and weight loss

These approvals mark critical milestones, reinforcing the shift towards more diverse and innovative treatment strategies that are enticing to patients, broadening the scope of non-invasive options available to healthcare providers

Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists

Your doctor says you need a GLP-1 for weight loss only

Though his HbA1c level dropped after adding the SU, over 2 years it has crept up to 8.6% and his mean blood glucose is 186 mg/dL